Current Cardiology Reviews最新文献

{"title":"The First 21-year Bibliometric Analysis of Renal Denervation for Heart Failure (2004-2024): Mapping Global Trends and Future Directions.","authors":"Jie Liu, Xiao Wang, Gangjun Zong, Yehong Liu, Ying Sheng, Jiangping Ye, Rikang Yuan","doi":"10.2174/011573403X396475251202094236","DOIUrl":"10.2174/011573403X396475251202094236","url":null,"abstract":"<p><strong>Introduction: </strong>This pioneering bibliometric analysis aims to evaluate the global research landscape and evolving trends of Renal Denervation (RDN) as an emerging therapy for Heart Failure (HF) over the past two decades (2004-2024).</p><p><strong>Methods: </strong>Utilizing tools including Bibliometrix, VOSviewer, and CiteSpace, we analyzed 222 English publications (135 articles; 87 reviews) from the Web of Science Core Collection. The study assessed publication trends, international collaborations, keyword co-occurrence, and thematic evolution.</p><p><strong>Results: </strong>Annual publications surged consistently post-2012. Leading contributing countries were the U.S. (37.4%), China (17.6%), and Germany (16.7%). Research focus shifted from foundational mechanistic insights to clinical applications, particularly in heart failure with reduced ejection fraction (HFrEF). Key findings demonstrated RDN's association with improved cardiac function, reduced NT-proBNP, and enhanced exercise tolerance.</p><p><strong>Discussion: </strong>The findings affirm RDN's potential as a transformative intervention for sympathetic- driven HF, especially HFrEF, by addressing neurohormonal overactivation. Current evidence supports its efficacy, though limitations include a lack of randomized trials in HFpEF and standardized procedural protocols. Future directions should emphasize phenotype-specific trials and biomarker-guided patient selection.</p><p><strong>Conclusion: </strong>RDN represents a promising precision therapy for HF. Accelerating its clinical translation requires multidisciplinary collaboration, dedicated funding for trial validation, and integration of multi-omics and artificial intelligence for personalized treatment strategies.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory Biomarkers in Coronary Artery Disease: Diagnostic and Prognostic Potential?","authors":"Rahul Ghelani, Bashir Alaour","doi":"10.2174/011573403X457005260226155043","DOIUrl":"https://doi.org/10.2174/011573403X457005260226155043","url":null,"abstract":"<p><strong>Introduction: </strong>Coronary artery disease (CAD) is a leading global cause of morbidity and mortality. Advances in treatment have resulted in a new, growing cohort of patients who require lifelong management. Although inflammation is firmly established as a driving force across all stages of atherosclerosis, the potential role of inflammatory biomarkers in improving disease prediction, phenotyping, and risk stratification remains uncertain and continues to be debated.</p><p><strong>Objectives: </strong>To examine the current evidence surrounding inflammatory biomarkers that demonstrate potential utility in the assessment of CAD across three key domains: (i) predicting incidence of CAD in asymptomatic individuals; (ii) predicting plaque rupture in patients with established CAD; and (iii) forecasting recurrent cardiovascular events and relevant adverse clinical outcomes, following an acute coronary syndrome.</p><p><strong>Methods: </strong>We undertook a structured literature search using Embase (OVID), combining relevant MeSH terms and keywords. Boolean operators, truncation, and wildcards were used to further refine results, with sub-analyses undertaken on both recent (≤5 years) and earlier foundational studies.</p><p><strong>Results: </strong>Biomarkers critically assessed range from established agents such as C-reactive protein and Fibrinogen to those currently utilised in a research capacity, including Interleukin-6, Galectin-3, Myeloperoxidase, and Tumour necrosis factor-alpha. We additionally discuss the conceivable clinical translation of each biomarker in the context of any key barriers to use.</p><p><strong>Discussion and conclusions: </strong>Inflammatory biomarkers have the potential to improve coronary disease assessment, but do not currently hold an established place in the diagnosis, risk stratification, or prognostication of disease. Validating their clinical applications along different phases of the atherosclerotic process remains a distant but worthwhile target.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental Health and Substance Use Disorders in Advanced Heart Failure Patients Undergoing VAD Implantation and Cardiac Transplantation: How Much do We Know?","authors":"Nandini Nair, Chloe Grzyb, Dongping Du, Balakrishnan Mahesh","doi":"10.2174/011573403X386810251211163644","DOIUrl":"10.2174/011573403X386810251211163644","url":null,"abstract":"<p><strong>Background: </strong>Patients who undergo cardiac transplantation or implantation of LVADs are significantly affected by mental health disorders and substance use problems, which can negatively impact their compliance and quality of life. There is a paucity of research regarding mental health and substance abuse disorders in the post-LVAD implant/ cardiac transplant population. This narrative review will focus on the knowledge gaps </P> Methods: A qualitative review was performed by conducting a literature search using PubMed and Google Scholar. Adults 18 years and older with LVAD or cardiac transplant were included. The keywords used were anxiety, depression, mood disorder, panic disorder, PTSD, adjustment disorder, and eating disorders in LVAD patients, and anxiety, depression, mood disorder, panic disorder, PTSD, and adjustment disorder in heart transplant patients. No geographical parameters were used in the search. All papers retrieved were reviewed qualitatively, and relevant information obtained was synthesized to arrive at the results and conclusions presented in this review. </P> Results: This narrative review showed that anxiety, depression, mood disorder, panic disorder, PTSD, adjustment disorder, and eating disorder exist in patients undergoing advanced surgical therapies (durable LVADs and cardiac transplantation). Most of the relevant studies are retrospective chart analyses done in single centers. Incidence and prevalence vary widely. </P> Discussion: This review highlights the importance of mental health surveillance in patients undergoing LVAD and cardiac transplantation to enhance outcomes by improving behavioral health and compliance. </P> Conclusions: There are no granular guidelines to address psychosocial evaluation in this population. The current literature does not help to distinguish any differences mechanical support would have on the psychology of these patients as compared to cardiac transplantation. Knowledge gaps exist in risk assessment and risk stratification of patients, which need further investigation.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147462534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Cerebral and Organ Perfusion Protection Following Reconstructive Surgeries on the Aortic Arch in Newborns.","authors":"Ilya A Velyukhanov, Ilya A Soynov, Artem V Gorbatykh, Serezha N Manukian, Olga S Anikina, Yuriy Yu Kulyabin, Natalya R Nichay, Aleksey N Arkhipov, Valeriy A Nepomniashikh, Igor A Kornilov","doi":"10.2174/011573403X404858251126101458","DOIUrl":"10.2174/011573403X404858251126101458","url":null,"abstract":"<p><strong>Introduction: </strong>To assess the efficacy and safety of whole-body perfusion in newborn patients after reconstructive surgeries on the aortic arch.</p><p><strong>Methods: </strong>In this retrospective study with propensity score matching (PSM), we evaluated the efficacy and safety of surgical treatment in newborn patients after reconstructive surgeries on the aortic arch using whole-body perfusion (n=43) and selective antegrade cerebral perfusion (n=117).</p><p><strong>Results: </strong>After PSM, patients were divided into two well-balanced groups: the whole-body perfusion (WBP) group (n=40) and the selective antegrade cerebral perfusion (SACP) group (n=40). Acute kidney injury was observed in 22.5% of patients in the WBP group, compared to 47.5% of patients in the SACP group (p=0.034). Risk factors for acute kidney injury included the method of SACP (OR 95% CI 6.1 [1.6, 19.8]) and the inotropic index on the first day (OR 95% CI 1.09 [1.01, 1.20]). Neurological complications occurred in 9.3% of patients in the WBP group and 11.6% in the SACP group (p>0.99). The only risk factor for neurological complications was low birth weight (OR 95% CI 4.5 [2.8, 16.2], p=0.042). Postoperative mortality did not differ between groups: 2.4% in the WBP group versus 4.6% in the SACP group (p>0.99).</p><p><strong>Discussion: </strong>Perfusion techniques for neonatal aortic arch reconstruction have evolved from deep hypothermic circulatory arrest to selective antegrade cerebral perfusion with a recent trend toward combining SACP with lower body perfusion, a strategy known as whole-body perfusion. While DHCA is still utilized in pediatric cardiac surgery, it is associated with a high risk of postoperative complications, particularly affecting the brain and internal organs. SACP has demonstrated effective cerebral protection and has been widely adopted. Detailed studies of SACP's neuroprotective strategy have enabled its safe implementation without deep hypothermia, allowing procedures to be performed at temperatures up to 26°C.</p><p><strong>Conclusion: </strong>Whole-body perfusion during aortic arch surgery in newborns is an effective and safe organ protection technique that may reduce the incidence of acute kidney injury. A high vasoactiveinotropic score (VIS) was identified as a significant postoperative risk factor for acute kidney injury. However, prospective studies are needed to further validate the advantages of whole-body perfusion.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147462601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Gene Therapies and Novel Treatment Strategies for Infiltrative Cardiomyopathies: A Comprehensive Review of Targeted Interventions.","authors":"Sasan Shafiei, Roozbeh Narimani Javid, Negar Haratian, Zahrasadat Moayedi, Maryam Aghakouchakzadeh, Fatemeh Najafinezhad, Salar Azadnik, Seyedeh Maryam Hoseini, Salma Nozhat, Reza Laripour, Reyhaneh Ettehadi, Mohammad Zareei, Fatemeh Ghanbari, Malihe Taghizadeh Ghassab, Ghazal Ansarifahlyani, Alireza Arzhangzade","doi":"10.2174/011573403X363296251202125302","DOIUrl":"https://doi.org/10.2174/011573403X363296251202125302","url":null,"abstract":"<p><p>Recent progress in unraveling the molecular mechanisms of infiltrative Cardiomyopathies (CMPs) has created exciting opportunities for targeted therapies. These conditions, which include cardiac amyloidosis, sarcoidosis, Danon disease, Fabry disease, Mucopolysaccharidoses (MPS), and cardiac oxalosis, significantly impair cardiac function through complex pathogenic mechanisms. In cardiac amyloidosis, the accumulation of misfolded proteins into fibrillary amyloids disrupts myocardial structure, leading to inflammation, oxidative stress, and apoptosis. New treatments such as Antisense Oligonucleotides [ASOs], small interfering RNA [siRNA], and monoclonal antibodies have shown promising results in preclinical and clinical settings for managing amyloid deposition. Gene editing technologies, particularly CRISPR-Cas9, also have significant potential to deliver lasting therapeutic benefits by precisely correcting pathogenic mutations. Furthermore, managing Fabry disease with Enzyme Replacement Therapies [ERT] and chaperone molecules has improved cardiac outcomes; however, challenges remain in advanced stages due to ongoing myocardial involvement. Immunomodulatory strategies and innovative antibody-based therapies targeting pathological protein aggregates represent groundbreaking approaches that have shown efficacy in preclinical and earlyphase clinical trials. Despite these advancements, challenges remain, including the efficiency of drug delivery, possible off-target effects, and inconsistent clinical responses among different patient groups. Future research should focus on improving these therapies to increase their specificity and safety, ultimately enhancing patient outcomes and quality of life in infiltrative cardiomyopathies.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy and Safety of Zero-Fluoroscopy and Standard Transcatheter VSD Closure: A Systematic Review and Meta-Analysis.","authors":"Zuhair Amir Alkatiri, Muhammad Dzaky Erlangga Mumtaz, Muhammad Hatta Hakim, Rizqi Indirsyah Faiq, Ramy Iftikhar Mulyana, Muhammad Bimo Ramadhan, Radityo Prakoso","doi":"10.2174/011573403X412195251127045109","DOIUrl":"10.2174/011573403X412195251127045109","url":null,"abstract":"<p><strong>Introduction: </strong>The Zero-Fluoroscopy (ZF) approach has emerged as an alternative technique for transcatheter ventricular septal defect (VSD) closure, eliminating radiation exposure by relying solely on echocardiographic guidance. This method is particularly beneficial for pediatric patients. However, its efficacy and safety compared to the standard fluoroscopy-guided approach remain uncertain.</p><p><strong>Methods: </strong>A systematic review was conducted following PRISMA guidelines. Data were retrieved from four databases. Studies reporting procedural success, complications, or procedural outcomes were included. Meta-analysis was performed using RStudio with a 95% CI, and subgroup comparisons were assessed.</p><p><strong>Results: </strong>A total of 62 studies, including 5,020 patients (mean age 11.11 years), were analyzed. Nine studies utilized the ZF approach. The success rate was 95.5% (91.7-98.3%) for the ZF group and 98.0% (97.1-98.8%) for the fluoroscopy group, with no statistically significant difference (p = 0.08), indicating non-inferiority. The early residual shunt rate was significantly lower in the ZF group (5.5%, 0.1-15.8%) compared to the fluoroscopy group (20.8%, 15.7- 26.4%) (p < 0.05). Other complications, including new-onset conduction block (p = 0.12) and new-onset valvular regurgitation (p = 0.29), showed no significant differences.</p><p><strong>Discussion: </strong>ZF closure shows similar success and safety to the standard approach, with the added benefit of reduced residual shunt and radiation exposure.</p><p><strong>Conclusions: </strong>ZF is a safe, effective alternative to fluoroscopy-guided VSD closure, particularly suited for reducing radiation risks in pediatric and vulnerable patients.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic and Side Effects of Enoxaparin over Heparin on Acute Coronary Syndrome Patients in Bali.","authors":"Rini Noviyani, I Gusti Ayu Widha Paramistya Devi, I Made Putra Swi Antara, Agata Widtama, Sagung Chandra Yowani","doi":"10.2174/011573403X414877251124225616","DOIUrl":"10.2174/011573403X414877251124225616","url":null,"abstract":"<p><strong>Introduction: </strong>Acute Coronary Syndrome (ACS) is a major cause of morbidity and mortality worldwide. Anticoagulant therapies such as enoxaparin and heparin are commonly used to reduce thrombotic events, but their comparative efficacy and safety profiles remain to be fully established. This study aimed to compare the therapeutic effects and side effects of enoxaparin versus heparin in patients with ACS treated at hospitals in Bali. No randomization or blinding was performed in this observational study due to its retrospective design. This study was conducted as a cross-sectional observational study by reviewing medical records of patients diagnosed with Acute Coronary Syndrome (ACS) treated at Prof. Dr. I.G.N.G. Ngoerah Hospital and RSUD Tabanan from January 2021 to December 2023, Bali, Indonesia.</p><p><strong>Methodology: </strong>A retrospective cross-sectional observational study was conducted by reviewing medical records of ACS patients treated at Prof. Dr. I.G.N.G. Ngoerah Hospital and RSUD Tabanan, Bali, Indonesia, from January 2021 to December 2023. No randomization or blinding was performed due to the observational design. Sample size was calculated using the Lemeshow formula, with a minimum of 66 patients required. The primary outcomes were recurrence of myocardial infarction (MI) and mortality, while bleeding events were secondary outcomes. Logistic regression was employed to adjust for confounders, including age, sex, hypertension, diabetes, chronic kidney disease, and ACS subtype, Bali, Indonesia.</p><p><strong>Results: </strong>Among 73 patients (60 receiving enoxaparin, 13 receiving heparin), MI recurrence rates were 6.7% and 0%, mortality rates were 3.3% and 30.8%, and bleeding incidence was 5% and 7.7%, respectively. Mortality was significantly lower in the enoxaparin group (p = 0.008). Adjusted logistic regression revealed that hypertension significantly increased bleeding risk (adjusted OR = 29.4; 95% CI: 1.02-844.0; p = 0.049), while other factors showed no significant association.</p><p><strong>Discussion: </strong>The results suggest that enoxaparin is associated with lower mortality compared to heparin without significant differences in MI recurrence or bleeding events. The strong association between hypertension and bleeding highlights the need for careful management of hypertensive ACS patients. However, wide confidence intervals and small sample size warrant cautious interpretation, and further large-scale prospective studies are needed.</p><p><strong>Conclusion: </strong>Enoxaparin appears to be more effective in reducing mortality than heparin in ACS patients, with hypertension identified as a significant risk factor for bleeding. These findings support the preferential use of enoxaparin in this population, pending validation from larger studies.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147462541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Pharmacovigilance Analysis of Drug-Induced Decreased Cardiac Ejection Function: Evidence from the FAERS Database (2004-2024).","authors":"Zhuhua Wang, Shupeng Chen, Guilian He, Nana Tang, Zhongyong Liu","doi":"10.2174/011573403X416240251125055245","DOIUrl":"10.2174/011573403X416240251125055245","url":null,"abstract":"<p><strong>Introduction: </strong>Decreased Cardiac Ejection Function (DCEF) is a critical manifestation of cardiotoxicity and has been increasingly recognized as a potential adverse effect of pharmacotherapy, particularly with antineoplastic and immunomodulating agents. This study conducted a comprehensive pharmacovigilance assessment of drug-induced DCEF using the FDA Adverse Event Reporting System (FAERS), focusing on high-risk drug identification, onset timing, and pharmacological classification.</p><p><strong>Methods: </strong>FAERS reports from 2004 to 2024 were standardized using MedDRA and RxNorm. Disproportionality analysis with Reporting Odds Ratios (ROR) and 95% Confidence Intervals (CI) was used to detect drug-event associations. Time-to-Onset (TTO) analysis was performed for five clinically relevant agents, doxorubicin, docetaxel, rituximab, dabrafenib, and bevacizumab, selected based on frequency, signal strength, and clinical importance. Weibull modeling was used to characterize temporal risk patterns.</p><p><strong>Results: </strong>A total of 86 drugs were significantly associated with DCEF. Frequently reported agents included trastuzumab (1,183 cases) and doxorubicin (465 cases). Notably, 50 drugs (e.g., clozapine, rofecoxib, docetaxel) were not previously labeled for DCEF, representing novel safety signals. Time-to-onset analysis showed that all five evaluated agents followed an \"earlyfailure\" pattern (β < 1), meaning the risk of DCEF was highest shortly after treatment initiation and declined thereafter. Median TTO ranged from 42 days for rituximab (β = 0.52, 95% CI: 0.41-0.63) to 140 days for doxorubicin (β = 0.83, 95% CI: 0.68-0.97; α = 277.8, 95% CI: 187.6-367.9), suggesting variable latency between drugs. Demographically, patients aged 65-85 years (22.9% of known cases) and those with body weight 70-89 kg (10.2%) were most frequently affected.</p><p><strong>Conclusion: </strong>This large-scale real-world analysis identifies both established and novel DCEF risk signals, highlights heterogeneity in onset timing, and emphasizes the predominance of antineoplastic agents. Clinically, these findings suggest the need for periodic echocardiographic monitoring of left ventricular ejection fraction, particularly in patients receiving high-risk drugs such as mitoxantrone, trastuzumab, doxorubicin, and pertuzumab. Early-phase monitoring is crucial for \"early-failure\" agents, while extended follow-up is warranted for drugs with delayed toxicity, such as doxorubicin. These results provide actionable evidence to support individualized risk management and regulatory label updates.</p>.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the Long-term Outcomes of Coronary Artery Bypass Grafting (CABG) vs. Percutaneous Coronary Intervention (PCI) in Patients with Multivessel Disease- A Systematic Review and Meta-Analysis.","authors":"Rubela Ray, Shivam Singla, Ghazala S Virk, Sarah Hack, Zaghum Abbas, Hemamalini Anand Murugesan, Arhum Mahmood, Mahnoor Shah, Samra Khalid, Sana Afzal, Izzat Izzat","doi":"10.2174/011573403X402044251204104520","DOIUrl":"10.2174/011573403X402044251204104520","url":null,"abstract":"<p><strong>Introduction: </strong>Coronary Artery Bypass Grafting (CABG) and Percutaneous Coronary Intervention (PCI) are standard treatments for Multivessel Coronary Artery Disease (MVD). Their long-term comparative effectiveness remains debated.</p><p><strong>Method: </strong>A systematic review and meta-analysis of randomized and observational studies was conducted, including patients with MVD followed for ≥5 years. Data were pooled using randomor fixed-effects models, depending on the level of heterogeneity.</p><p><strong>Results: </strong>Thirteen studies met the inclusion criteria. CABG was associated with reduced all-cause mortality (RR 0.82, 95% CI 0.72-0.91) and fewer repeat revascularizations (RR 1.98, 95% CI 1.74-2.26) compared with PCI. Stroke risk was slightly higher after CABG.</p><p><strong>Discussion: </strong>Findings suggest CABG provides superior survival and event reduction in long-term follow-up, particularly in higher-risk subgroups. However, the modestly increased stroke risk highlights the need for individualized decision-making, taking into account patient comorbidities, anatomy, and surgical suitability.</p><p><strong>Conclusion: </strong>CABG offers long-term survival and durability advantages over PCI in MVD, while PCI remains suitable for patients with lower-risk anatomy or when surgery is contraindicated.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147462547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Piperine Protects Against Arsenic Trioxide-Induced Cardiotoxicity in Rats: A Biochemical and Electrocardiography Study.","authors":"Gayatri Khuntia, Jeevan Ranjan Dash","doi":"10.2174/011573403X397560251202145628","DOIUrl":"https://doi.org/10.2174/011573403X397560251202145628","url":null,"abstract":"<p><strong>Introduction: </strong>Arsenic trioxide is a highly effective chemotherapeutic agent that counteracts acute promyelocytic leukemia. However, the use of arsenic trioxide for managing acute promyelocytic leukemia has been associated with severe cardiotoxic effects. We investigated the cardioprotective effect of piperine in arsenic trioxide-induced cardiotoxicity in rats.</p><p><strong>Methods: </strong>Cardiotoxicity was induced by administration of arsenic trioxide at 4 mg/kg body weight (bwt) orally for 30 days. The cardioprotective effect of piperine at 20 mg/kg orally was studied by cardiac biomarkers, oxidative parameters, and an electrocardiography study.</p><p><strong>Results: </strong>Administration of arsenic trioxide at 4 mg/kg bwt orally for 30 days caused significant cardiovascular injury, confirmed by elevated cardiac enzymes CK-MB and LDH levels. Electrocardiographic (ECG) abnormalities were notable in the arsenic trioxide-treated group, such as prolonged QT and QTc intervals and reduced heart rate. There was significant myocardial oxidative impairment (TBARS increased, SOD and Catalase decreased) and inflammation (IL-6 increased).</p><p><strong>Discussion: </strong>When piperine at 20 mg/kg was used, it decreased the CK-MB and LDH levels, reduced the prolonged QT and QTc intervals, and improved oxidative damage and inflammation.</p><p><strong>Conclusion: </strong>This study demonstrated that piperine at 20 mg/kg orally was protective in arsenic trioxide-induced cardiotoxicity in an experimental rat model. This study is the first to combine serum biomarkers and ECG analysis to demonstrate piperine's cardioprotective role. It may have clinical relevance in exploring the potential of piperine to reduce arsenic trioxide-induced cardiotoxicity.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}